We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
P8‐120: Therapeutic efficacy of osimertinib following afatinib for the rare EGFR mutation exon19 delL747_P753insS: A case report.
- Abstract
1 Department of Respiratory Medicine, Okayama University Hospital, Japan B Background b : Epidermal growth factor receptor (EGFR) mutation, exon 19 deletion and L858R point mutation, are commonly used as biomarkers to predict EGFR-tyrosine kinase inhibitor (TKI) responses. However, whether patients with the rare EGFR mutation exon19 delL747 P753insS (delL747 P753insS) respond to EGFR-TKIs remains controversial. P8-120: Therapeutic efficacy of osimertinib following afatinib for the rare EGFR mutation exon19 delL747 P753insS: A case report.
- Subjects
EPIDERMAL growth factor receptors; OSIMERTINIB; AFATINIB; GENETIC mutation; TREATMENT effectiveness
- Publication
Respirology, 2021, Vol 26, p335
- ISSN
1323-7799
- Publication type
Article
- DOI
10.1111/resp.14150_632